BOSTON & SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc.(NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women’s Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString’s Elements™ reagents, assays will be developed to detect gene expression, copy number variations, and fusions from a diverse range of tumor samples.
NanoString’s nCounter® Analysis System is an automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays across a number of important research applications. The research collaboration will enable the researchers at Brigham and Women’s Hospital to evaluate and analyze a repository of patient derived tumor tissues for identification of gene signatures and gene expression profiles that typify a specific tumor type. This knowledge is expected to fuel the development of validated diagnostic tests with potential to vastly improve clinical decisions involved in treatment of cancer patients. Under the terms of the agreement, NanoString retains the right to license diagnostic content developed within the scope of the collaboration.
Help employers find you! Check out all the jobs and post your resume.
NanoString’s nCounter® Analysis System is an automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays across a number of important research applications. The research collaboration will enable the researchers at Brigham and Women’s Hospital to evaluate and analyze a repository of patient derived tumor tissues for identification of gene signatures and gene expression profiles that typify a specific tumor type. This knowledge is expected to fuel the development of validated diagnostic tests with potential to vastly improve clinical decisions involved in treatment of cancer patients. Under the terms of the agreement, NanoString retains the right to license diagnostic content developed within the scope of the collaboration.
Help employers find you! Check out all the jobs and post your resume.
